Business context and reporting period
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) filed this unaudited Form 10-Q for the quarter and nine months ended September 30, 2023. Its commercial-stage business spans Immune Medicine, including immunoSEQ and biopharmaceutical collaborations, and Minimal Residual Disease (MRD), including the clonoSEQ diagnostic and MRD research services.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $37.9m | $47.8m | $124.5m | $130.1m |
| Gross margin | 48.9% | 68.8% | 55.1% | 68.2% |
| Operating loss | $51.0m | $45.4m | $156.0m | $161.0m |
| Net loss attributable to Adaptive | $50.3m | $45.3m | $155.8m | $160.1m |
| Adjusted EBITDA (non-GAAP) | $(29.8)m | $(25.9)m | $(91.7)m | $(102.0)m |
Basic and diluted loss per share was $0.35 in Q3 and $1.08 for the nine-month period, versus $0.32 and $1.12, respectively, in 2022. Q3 operating expenses totaled $88.9m; nine-month expenses were $280.5m.
At September 30, cash and cash equivalents were $88.7m and short-term marketable securities were $282.4m, totaling $371.1m. Current assets were $435.2m against current liabilities of $93.3m. Operating cash use was $129.4m for the nine months, compared with $153.9m a year earlier; capital expenditures were $9.4m. Cash, cash equivalents and restricted cash totaled $91.6m.
The company reported a $129.9m net revenue-interest liability under its OrbiMed purchase agreement, recorded as debt, with an effective interest rate of 11.3%. It may request up to an additional $125m by September 2025, subject to funding conditions. Operating lease liabilities totaled $101.3m.
Material changes versus the prior comparable period
- Q3 revenue fell 21%, as Immune Medicine revenue declined 52%, primarily reflecting lower Genentech collaboration revenue. MRD revenue rose 24%, driven by clonoSEQ clinical services.
- Nine-month revenue declined 4%. MRD revenue increased 22%, but Immune Medicine revenue fell 26%; the prior-year period included $4.0m of MRD regulatory milestone revenue, versus none in 2023.
- clonoSEQ test volume increased 56% in Q3 to 15,072 tests and 55% year to date to 40,816 tests.
- Cost of revenue rose 30% in Q3 and 35% year to date, with lab relocation and consolidation costs contributing to the increase. Gross margin consequently declined year over year.
- Research and development spending fell 20% in Q3 and 16% year to date, principally due to lower investment in T-Detect, TCR-Antigen Map and drug discovery activities. Higher interest income partly offset the increased interest expense from the OrbiMed agreement.
Outlook, commentary and risks
Management believes existing cash, cash equivalents and marketable securities will fund operating expenses and capital expenditure requirements for at least the next 12 months. It expects long-term revenue growth, while acknowledging near-term variability. Planned uses of cash include drug discovery research, clonoSEQ commercial and marketing activities, and laboratory-efficiency initiatives. No specific revenue or earnings guidance is provided.
Management deferred further T-Detect commercialization pending stronger data across disease states and a clearer reimbursement path. Genentech revenue depends on collaboration activities and may fluctuate with development costs and decisions; Genentech revenue represented 23.2% of Q3 revenue and 30.0% of nine-month revenue. The company disclosed up to $399.5m of potential future MRD milestone payments, contingent on customers’ regulatory approvals. Such milestones are uncertain and are not recognized until applicable revenue-recognition criteria are met.
Other risks include continued operating losses and negative operating cash flow, reliance on certain suppliers, reimbursement and customer-project uncertainties, and the possibility that additional financing may be needed; future equity financing could dilute shareholders. The filing reported no material legal proceedings, no material changes to previously disclosed risk factors, and effective disclosure controls as of September 30, 2023.
Important facts for investors to verify
- Whether clonoSEQ volume growth translates into sustained revenue growth and improved gross margins.
- How collaboration revenue, especially Genentech, evolves and whether milestone or royalty payments are achieved.
- Operating cash burn and the runway implied by the $371.1m cash and marketable-securities balance.
- The future cost and repayment profile of the revenue-interest liability, including any additional OrbiMed funding.
- Whether reduced research and development investment affects pipeline progress or planned product development.